Literature DB >> 28004223

Identification of MSH2 inversion of exons 1-7 in clinical evaluation of families with suspected Lynch syndrome.

Maureen E Mork1, Andrea Rodriguez2, Melissa W Taggart3, Miguel A Rodriguez-Bigas1,4, Patrick M Lynch1,5, Sarah A Bannon1, Y Nancy You1,4, Eduardo Vilar6,7,8.   

Abstract

Traditional germline sequencing and deletion/duplication analysis does not detect Lynch syndrome-causing mutations in all individuals whose colorectal or endometrial tumors demonstrate mismatch repair (MMR) deficiency. Unique inversions and other rearrangements of the MMR genes have been reported in families with Lynch syndrome. In 2014, a recurrent inversion of MSH2 exons 1-7 was identified in five families suspected to have Lynch syndrome. We aimed to describe our clinical experience in identifying families with this specific inversion. Four probands whose Lynch syndrome-associated tumors demonstrated absence of MSH2/MSH6 staining and who had negative MMR germline testing were evaluated for the MSH2 inversion of exons 1-7, offered during initial genetic workup or upon routine clinical follow-up. All four probands tested positive for the MSH2 inversion. Proband cancer diagnoses included colon and endometrial adenocarcinoma and sebaceous adenoma. A variety of Lynch syndrome-associated cancers were reported in the family histories, although only one family met Amsterdam II criteria. Thirteen at-risk relatives underwent predictive testing. MSH2 inversion of exons 1-7 was found in four probands previously suspected to have Lynch syndrome based on family history and tumor testing. This testing should be offered routinely to patients with tumors demonstrating loss of MSH2/MSH6 staining.

Entities:  

Keywords:  Lynch syndrome; MSH2 inversion; Mismatch repair

Mesh:

Substances:

Year:  2017        PMID: 28004223      PMCID: PMC5479758          DOI: 10.1007/s10689-016-9960-y

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  12 in total

1.  The 10-Mb paracentric inversion of chromosome arm 2p in activating MSH2 and causing hereditary nonpolyposis colorectal cancer: re-annotation and mutational mechanisms.

Authors:  Jian-Min Chen
Journal:  Genes Chromosomes Cancer       Date:  2008-06       Impact factor: 5.006

2.  Classifying MMR variants: time for revised nomenclature in Lynch syndrome.

Authors:  Y Nancy You; Eduardo Vilar
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

3.  Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population.

Authors:  Jennifer Rhees; Mildred Arnold; C Richard Boland
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

4.  Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.

Authors:  Willemina R R Geurts-Giele; Celine H M Leenen; Hendrikus J Dubbink; Isabelle C Meijssen; Edward Post; Hein F B M Sleddens; Ernst J Kuipers; Anne Goverde; Ans M W van den Ouweland; Margot G F van Lier; Ewout W Steyerberg; Monique E van Leerdam; Anja Wagner; Winand N M Dinjens
Journal:  J Pathol       Date:  2014-09-30       Impact factor: 7.996

5.  Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome.

Authors:  Monika Morak; Udo Koehler; Hans Konrad Schackert; Verena Steinke; Brigitte Royer-Pokora; Karsten Schulmann; Matthias Kloor; Wilhelm Höchter; Josef Weingart; Cortina Keiling; Trisari Massdorf; Elke Holinski-Feder
Journal:  J Med Genet       Date:  2011-06-28       Impact factor: 6.318

6.  A cryptic paracentric inversion of MSH2 exons 2-6 causes Lynch syndrome.

Authors:  Qing Liu; Luke B Hesson; Andrea C Nunez; Deborah Packham; Rachel Williams; Robyn L Ward; Mathew A Sloane
Journal:  Carcinogenesis       Date:  2015-10-24       Impact factor: 4.944

7.  Risk of cancer in cases of suspected lynch syndrome without germline mutation.

Authors:  María Rodríguez-Soler; Lucía Pérez-Carbonell; Carla Guarinos; Pedro Zapater; Adela Castillejo; Victor M Barberá; Miriam Juárez; Xavier Bessa; Rosa M Xicola; Juan Clofent; Luis Bujanda; Francesc Balaguer; Josep-Maria Reñé; Luisa de-Castro; José C Marín-Gabriel; Angel Lanas; Joaquín Cubiella; David Nicolás-Pérez; Alejandro Brea-Fernández; Sergi Castellví-Bel; Cristina Alenda; Clara Ruiz-Ponte; Angel Carracedo; Antoni Castells; Montserrat Andreu; Xavier Llor; José L Soto; Artemio Payá; Rodrigo Jover
Journal:  Gastroenterology       Date:  2013-01-24       Impact factor: 22.682

8.  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.

Authors:  Marjolijn J L Ligtenberg; Roland P Kuiper; Tsun Leung Chan; Monique Goossens; Konnie M Hebeda; Marsha Voorendt; Tracy Y H Lee; Danielle Bodmer; Eveline Hoenselaar; Sandra J B Hendriks-Cornelissen; Wai Yin Tsui; Chi Kwan Kong; Han G Brunner; Ad Geurts van Kessel; Siu Tsan Yuen; J Han J M van Krieken; Suet Yi Leung; Nicoline Hoogerbrugge
Journal:  Nat Genet       Date:  2008-12-21       Impact factor: 38.330

Review 9.  Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications.

Authors:  H T Lynch; P M Lynch; S J Lanspa; C L Snyder; J F Lynch; C R Boland
Journal:  Clin Genet       Date:  2009-07       Impact factor: 4.438

10.  Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.

Authors:  Sigurdis Haraldsdottir; Heather Hampel; Jerneja Tomsic; Wendy L Frankel; Rachel Pearlman; Albert de la Chapelle; Colin C Pritchard
Journal:  Gastroenterology       Date:  2014-09-03       Impact factor: 22.682

View more
  4 in total

1.  Patients with unexplained mismatch repair deficiency are interested in updated genetic testing.

Authors:  Jessica Omark; Eduardo Vilar; Y Nancy You; Leslie Dunnington; Sarah Noblin; Blair Stevens; Maureen Mork
Journal:  Hered Cancer Clin Pract       Date:  2020-09-21       Impact factor: 2.857

Review 2.  Should All Individuals Be Screened for Genetic Predisposition to Cancer?

Authors:  Sarah Wedderburn; Terri P McVeigh
Journal:  Genet Res (Camb)       Date:  2021-01-09       Impact factor: 1.588

Review 3.  Lynch-like Syndrome: Potential Mechanisms and Management.

Authors:  Alejandro Martínez-Roca; Mar Giner-Calabuig; Oscar Murcia; Adela Castillejo; José Luis Soto; Anabel García-Heredia; Rodrigo Jover
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

4.  Germline and Tumor Sequencing as a Diagnostic Tool To Resolve Suspected Lynch Syndrome.

Authors:  Bernard J Pope; Mark Clendenning; Christophe Rosty; Khalid Mahmood; Peter Georgeson; Jihoon E Joo; Romy Walker; Ryan A Hutchinson; Harindra Jayasekara; Sharelle Joseland; Julia Como; Susan Preston; Amanda B Spurdle; Finlay A Macrae; Aung K Win; John L Hopper; Mark A Jenkins; Ingrid M Winship; Daniel D Buchanan
Journal:  J Mol Diagn       Date:  2020-12-29       Impact factor: 5.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.